Evaluation of the effect of dexamethasone in patients with Covid 19 and hypoxemia

In December 2019, a disease of unknown cause broke out in Wuhan and spread rapidly throughout the world. The disease was officially named -19 COVID by the World Health Organization (WHO). Recent evidence has shown that inflammation and hyperthyroidism play an important role in disease progression, especially in patients with severe involvement. Therefore, treatments that can reduce the inflammatory load or stop the cytokine production process are likely to be effective for patients with severe involvement. Therefore, in this study, we investigated the effect of dexamethasone in patients with coronary heart disease and hypoxemia . This study was performed as a clinical trial with a control group, with parallel groups, without blinding, phase 3. The study on the effect of dexamethasone for corona treatment in Shahid Beheshti and Forghani hospitals in Qom province was performed by reviewing the records of patients hospitalized with Covid-19 in March 1998 and April 1999 . This study was performed through random sampling method, block allocation. In this study, a number of patients who had received dexamethasone at a dose of 12 to 16 mg daily for at least 3 days were randomly selected and another group of patients with coronary artery disease in terms of underlying disease, sex, age and severity were selected. Pulmonary involvement was almost identical and the results were evaluated .

According to the results and considering the results of damping outcomes, disease severity and length of hospital stay after treatment, 28.9% died in the intervention group and 49.4% in the control group. The difference was significant. (pv = 0.04) In terms of length of hospital stay and mean hospital stay in the intervention group was significantly higher than the control group. (pv = 0.00)

Based on the results of this study, the use of corticosteroid drugs in the treatment of these patients is effective in controlling the disease process and reducing its severity .